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Currently, there are over 1,800 annotated human miRNAs, many of which have tissue-specific expression. Numerous studies have
highlighted their role in haematopoietic differentiation and proliferation, acting as master regulators of haematopoietic stem cell
function. Aberrant expression of miRNAs has been observed in haematological cancers, exhibiting unique expression signatures
in comparison to normal counterparts. Functional and target analyses as well as animal models have attempted to annotate
how different miRNA may contribute to the pathophysiology of these malignancies from modulating cancer associated genes,
functioning directly as oncogenes or tumour suppressor genes or acting as bystanders or regulators of the epigenetic mechanisms
in cancer. miRNAs have also been shown to play a role in modulating drug resistance and determining prognosis between the
various subtypes of blood cancers. This review discusses the important role that miRNAs play in haematological malignancies by
exploring associations that exist between the two and trying to examine evidence of causality to support the tantalising possibility
that miRNAs might serve as therapeutic targets in blood cancers.
1. Introduction
The haematological malignancies are a diverse group of
neoplastic diseases.They are representing the fifthmost com-
mon cancer in the UK and are among the twenty most
common causes of cancer deaths in the UK [1]. A com-
bination of clinical, cytogenetic, and genetic features and
immunophenotype and cell morphology are used to stratify
each of the haematological cancers further into subtypes [2].
Tumourigenesis has long been attributed to the alteration of
oncogenes and tumour suppressor genes [3]. However, the
discovery of non-protein-coding RNA, such as microRNAs
(miRNAs) and their possible associations with cancer, has
certified suspicions that tumour pathogenicity is far more
complex than the simple deregulation of protein-coding
genes and warrants further investigation.
There are currently 1,862 miRNAs annotated in humans
[4], most of which are evolutionarily conserved. miRNAs
are 20–22 nucleotide transcripts in their mature form and
function to inhibit gene expression via negative regulation
of mRNA at a posttranscriptional level [5] (Figure 1). In
vivo mice studies have illustrated that disruption of miRNA
biogenesis through depletion of Dicer leads to embryological
and developmental arrest and subsequent incompatibility
with life [6]. miRNAs have since been demonstrated to
be vital in other essential biological processes such as
metabolism [5, 7], proliferation and differentiation [5, 8],
apoptosis [5, 9] and haematopoietic lineage differentiation
[5]. Considering that proliferation, differentiation, and reg-
ulation of apoptosis are fundamental hallmarks of cancer
development, it is unsurprising that miRNAs have also been
linked to tumourigenesis. The notion that miRNA may be
involved in cancer pathogenesis came from studies by Calin
et al. who noted that the location of approximately 50%
of miRNA genes correlated to cancer-associated genomic
regions (CAGRs) or fragile sites [10].
Perturbed miRNA expression in haematological cancers
alone cannot certify a direct and causal link between miRNA
and cancer development or progression [3]. However, where
many studies have solely identified a loose association
between certain haematological cancers and aberrantmiRNA
expression, others have been able to illustrate their role as
oncogenic or tumour suppressors in nature through vali-
dation of cancer associated targets, and these miRNAs will
primarily be the focus of this review.
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2. miRNA and the Haematological
Malignancies
2.1. The Chronic Leukaemias. The mass expansion of mature
B cells in the bonemarrow that characterises chronic lympho-
cytic leukaemia (CLL) is largely a result of defective apoptosis
rather than excess proliferation [3, 12] andmany of these cells
are halted in cell cycle progression at the G0/G1 phase [12].
Overexpression of the antiapoptotic BCL2 gene is frequently
found in patients [12]. CLL can be broadly divided into
two subgroups based on the presence or absence of somat-
ically mutated immunoglobulin variable heavy chain (IgVH)
genes and levels of zeta-chain-associated protein kinase 70
(ZAP70).These two factors have awidely accepted prognostic
value, with patients who exhibit IgVH mutations and low
ZAP70 levels fairing better [13]. Deletions of 13q14.3, 11q23,
and 6q12, as well as trisomy-12, are common abnormalities
associated with CLL [12].
In an attempt to further understand chromosome 13q14.3
deletions, it was found thatmiR-15a/16-1 were the only genes
localised to this region [14]. Cimmino et al. demonstrated an
inverse correlation between expression levels ofmiR-15a/16-1
in CLL cells in comparison to normal CD5+ lymphoid cells
extracted from patients or healthy controls, respectively [15].
Complementarity between these miRNAs and BCL2 was
found conserved both in humans and mice [15], and the
direct interaction ofmiR-15a andmiR-16-1was demonstrated
through reduced expression of a luciferase reporter con-
struct containing the BCL2 3󸀠UTR [15]. To confirm that
downregulation of miR15a/16-1 leads to apoptosis, the same
group identified apoptotic DNA fragments in MEG-01 cells
transfected with these miRNAs, and subsequent immunoblot
assays identified activation of APAF-1-caspase-9-PARP path-
way, illustrating that Bcl2 downregulation and subsequent
apoptosis bymiR-15a/16-1 are mediated through the intrinsic
apoptotic pathway [15]. These data demonstrate that miR-
15a/16-1 may act as bona fide tumour suppressor genes and
loss of function of these miRNAs possibly contributes to
CLL pathogenesis. Other work has further characterised
roles of miR-15a/16-1 in regulation of cell cycle control, with
many predicted targets of these miRNAs acting as important
regulators of the G0/G1 transition [16, 17]. Therefore, down-
regulation ofmiR-16 in haematological cancermay contribute
to uncontrolled cell cycle progression and tumourigenesis, as
well as defective cell apoptosis (Figure 2).
Only 60% of CLL patients demonstrate the 13q14.3 dele-
tion [18],meaning that highBCL2 expression inmost patients
cannot be explained by miR15a/16-1 downregulation alone.
Additionally, the majority of 13q14.3 deletions are mono-
allelic [16], suggesting additional aberrations of the remaining
alleles are required in order for miR-15a/16-1 to fulfil roles
as tumour suppressor genes according to Knudson’s two-hit
hypothesis [19]. An explanation might lie in the presence
of miRNA-associated mutations. In the CLL-prone New
Zealand black (NZB) mouse model, reduced expression
of miR-16-1 was identified secondary to a point mutation
in the 3󸀠DNA adjacent to the miR-16-1 region [20], and
Calin et al. demonstrated that a minority of CLL patients
possess germline mutations in pre-miR-15a/16-1 that affect
subsequent processing [21]. Despite controversy over the
mechanisms by which miR-15a/16-1 mediate their effects, it
is clear that these miRNAs play an important role in CLL
pathogenesis.
T-cell leukaemia-1 gene (TCL1) drives tumourigenesis
by activating the oncogene AKT, driving proliferation and
cell survival [22]. It plays a pathological role in CLL [23],
found highly expressed in patients with 11q deletion [24]
and correlating with aggressive malignancy (high ZAP70
levels and unmutated IgVH) [23, 24]. Overexpression ofTCL1
in these cases might be explained by a downregulation of
miR-181a and miR-29b, since both act to target TCL-1 [23].
miR-29b also targets antiapoptotic myeloid cell leukaemia
sequence 1 (MCL1) [25], an important lymphocytic survival
factor associated with CLL [26]. These tumour suppressor
miRNAs may make optimal treatment options for TCL1
or MCL1 expressing CLL patients [12]. Interestingly, miR-
181a has conversely shown upregulation in different mor-
phological subtypes of acute myeloid leukaemia (AML) [27],
demonstrating that certain miRNAsmay have dual functions
(tumour suppressor or oncogenic) depending on cell type and
context.
Abnormalities of the tumour suppressor gene tumour
protein 53 (TP53) can be found in CLL patients with chro-
mosome 17p13 aberrations [13]. Using real-time quantitative
polymerase chain reaction (qRT-PCR), patients with TP53
abnormalitieswere analysed for the expression of 35miRNAs.
Downregulation of p53-regulatedmiR-34awas demonstrated
[13]. Several genes involved in cell cycle progression and
linked to tumourigenesis (CDK4, CDK6, MYCN, Cyclin-E,
and E2F1) have been validated as direct targets of miR-34a
[13]. Additionally, levels of miR-29c and miR-17-5p were also
reduced. The latter is part of the miR-17-92 cluster and has
been shown to targetE2F1, p21, andCyclin-D1 [28], suggesting
a role as a tumour suppressor. A different study conversely
showed upregulation ofmiR-34a andmembers of themiR-29
family [29], and high expression of miR-331 in CLL patients,
suspected but not validated to target suppressor of cytokine
signalling 1 (SOCS1) [29, 30]. Reduced SOCS1 levels have
been previously found in cancers [31] and this would prevent
negative feedback of the JAK/STAT pathway andmight allow
cell proliferation, cell survival, and angiogenesis to progress
uninhibited [32].
Analysis of miRNA in CD19+ cells from peripheral blood
of CLL patients and healthy controls revealed deregulation
of various miRNAs, includingmiR-155,miR-150,miR-21, and
miR-101 [33]. Although potential targets were not discussed
within this study, some have previously shown experimen-
tally validated targets. Table 1 defines directly downregulated
targets validated by luciferase reporter assays as determined
by TarBase [30]. Particularly, the downregulation of PU.1
by miR-155 may be of relevance in CLL as multiple studies
have identified a correlation between PU.1 and lymphoid
tumourigenesis [34].
Chronic myeloid leukaemia (CML) is a clonal malig-
nancy of predominantly myeloid cells characterised by a
chronic phase (CML-CP) followed by an accelerated phase
and blast crisis (CML-BC) [35]. A hallmark of CML is
the well-characterised t(9; 22) aberration, otherwise known
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Figure 1:The basics of the biogenesis of miRNA. In most cases, RNA pol II transcribes long primary miRNA (pri-miRNA) transcripts which
are cleaved by the RNase III endonuclease Drosha, producing a pre-miRNA. Exportin-5 mediates pre-miRNA exit from the nucleus to the
cytoplasmwhere it is further processed by Dicer, another RNase III endonuclease, producing a 20–22 nucleotide mature miRNA duplex. One
strand of the duplex is incorporated into the protein complex RISC (RNA-induced silencing complex) based on its complementarity to the
3󸀠UTR of the mRNA. At this point, the mRNA is either posttranscriptionally silenced or degraded [11].
Table 1: Experimentally validated targets of miRNA overexpressed in Fulci et al. [33].
Experimentally validated targets (derived from TarBase [30])
miR-150 MYB and c-myb
miR-155
AGTR1, SMAD2, TP53INP1, BACH1, TAB2, SHIP1, Ets-1, JARID2, DHX40, NARS, ARID2, TRIP13, PHC2, PKN2,
PKIalpha, NF-𝜅B, PICALM, KBTBD2, UBQLN1, ETS1, PALD1, DET1, HIVEP2, LRRC59, ARL15, CSNK1A1, TLE4,
MRPS27, ZNF652, C16orf62, ZKSCAN5, FAM177A1, PDCD4, MASTL, ZNF273, MED13L, C3orf18, GATM, E2F2, NDS3,
VPS18, MCM8, ZNF28, PHF14, PAK2, SMARCA4, SBP2, SAC2, HBP1, LKAP, CCDC41, KLHL5, WEE1, DCUN1D2,
AGO4, WWC1, FAM91A1, MPP5, MRPL18, TM6SF1, APAF1, ARMC2, LCORL, RAB11FIP2, DRE2, WBP1L, RAPGEF2,
TRAK1, ZNF254, CEP41, LDOC1, TBC1D14, CYP2U1, IL17RB, MAP3K10, INTS6, FAM199X, INTS6, TSPAN14, PRKAR1A,
SAP30L, TAF5L, MATR3, LRIF1, MBNL3, MORC3, PHF17, CLUAP1, CARD11, LNX2, LSM14A, PCDH9, EXOSC2,
MEF2A, CARHSP1, ANAPC16, NFAT2CIP, PU.1, c-myb, C/EBP, BC0RL1, SHIP, RREB1, GNAS, NIK, and GPM6B
miR-21 PDCD4, PTEN, RECK, PPARa, TIMP3, TPM1, FasL, TGFBR2, SERPINB5, Pdcd-4, and CDK2AP1
miR-101 MYCN, ATP5B, EZH2, and MCL1
as the Philadelphia chromosome [35], which results in the
BCR-ABL fusion gene in over 95% of patients [36]. This
fusion protein is susceptible to tyrosine kinase inhibition, and
subsequently imatinib mesylate has been the gold standard
treatment [37]. However, evidence shows imatinib is unable
to fully inactivate BCR-ABL signals [36] and a number of
patients are resistant to this therapy [37], highlighting the
need to further understand the biology of CML.
Using qRT-PCR, Agirre and colleagues analysed 157
miRNAs in CD34+ cells between CML patients and healthy
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Figure 2: Comparison of possible downstream effects of miR-15a/16-1 during (a) healthy cells and (b) CLL cells. In healthy cells, high miR-
15a/16-1 expression results in appropriate silencing of targets BCL2,WT1, and cell cycle factors. In CLL, low miR-15a/16-1 expression results
in uninhibited expression of BCL2,WT1, and the cell cycle factors resulting in evasion of apoptosis and uncontrolled cell cycle progression.
donors. They found one upregulated miRNA (miR-96) and
four downregulated (miR-151, miR-150, miR-125a, and miR-
10a) that were able to consistently differentiate CML cells
from normal CD34+ cells in two separate cohorts [36].
Treatment of the Mo7e leukaemic cell line with imatinib
correlated with an upregulation of miR-150 and miR-151,
suggesting that in CML these miRNAs might be downreg-
ulated as a consequence of BCR-ABL1 activity [36]. The
same investigations suggest miR-10a is downregulated in
CML patients independent of BCR-ABL activity [36]. This
might help to explain the persistence of disease in some
patients despite imatinib therapy. In line with this hypothesis,
reexpression of miR-10a in CML CD34+ cells inhibited cell
growth, demonstrating its potential role as a tumour sup-
pressor in CML [36]. Gene array studies have identified high
expression of the transcription factor upstream stimulatory
factor 2 (USF2) in CML patients, and USF2 has been pro-
posed as amiR-10a target through computational algorithms
[36]. An association between the two was demonstrated,
as colon carcinoma RKO cells transfected with pre-miR-10a
showed a significant decrease in mRNA levels of USF2 [36].
Furthermore, predicted base pairing betweenUSF2 andmiR-
10a showed perfect complementarity and luciferase reporter
assays revealed that renilla luciferase activity of the USF2
3’UTR vector was significantly reduced in RKO cells when
transfected with miR-10a [36].
The BCR-ABL fusion gene also upregulates the miR-17-
92 cluster [38]. This cluster is conserved in the chromosome
13 open reading frame 25 (c13orf25) genomic region of
chromosome 13q31-32 and is transcriptionally regulated by
c-myc, which works cooperatively with BCR-ABL in CML
pathogenesis [38]. The cluster likely has an oncogenic role
in CML as overexpression induced proliferation in vitro [38].
Interestingly,miR-17-92 showed high expression in CML-CP,
but not in blast crisis CML-BC [38], despite this phase being
characterised by increased BCR-ABL activity [39]. Different
members of the miR-17-92 cluster affect genes whose inhi-
bition results in proliferation and inhibition of apoptosis,
such as E2F1, PTEN, and BIM [40]. These experiments
give an initial insight into different pathological mechanisms
between CML-CP and CML-BC.
A novel role of miRNA has been identified during blast
crisis. In this phase, increased BCR-ABL activity results in
aberrant activity of RNA binding proteins (RBPs) [39]. One
RBP affected is hnRNPE2 which arrests myeloid differentia-
tion through interaction with C/EBPa [41, 42]. Micro-array,
northern blot, and qRT-PCR approach identifiedmiR-328 as
downregulated in CML-BC secondary to BCR-ABL activity
both in vitro and in vivo [39]. Postulating that miRNA and
RBPs may interact, Eiring et al. showed that loss of miR-
328 in CML-BC is regulated by hnRNP-E2, as an inverse
correlation between the two exist, suggesting hnRNP-E2may
mediate miR-328 activity. They identified that the two can
interact and do so in a seed sequence independent manner.
Reexpression ofmiR-328 restores differentiation and impairs
blast survival not only through traditional seed sequence
dependent posttranscriptional silencing of the prosurvival
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factor PIM1, but also through interacting with hnRNP-
E2 (PCBP2), acting as a decoy to rescue C/EBPa mRNA
translation and function [39]. Another RBP, hnRNP-A1, is
also upregulated in CML-BC and has been shown to bind pri-
miR-17-92 [43], whichmight attempt to explain a lack ofmiR-
17-92 expression in CML-BC, as described previously.
2.2. The Acute Leukaemias. The chromosomal aberrations
in acute myeloid leukaemia (AML) are diverse. Some of
the common abnormalities include trisomy-8, monosomy-7,
translocations such as t(15; 17), t(8; 21), and the inversion of
chromosome 16 [35, 44, 45]. The latter three alterations gen-
erate the fusion proteins AML-ETO, PML-RARa, and CBFb-
MYH11, respectively [31]. Many patients with AML have a
normal karyotype and less than one-half of these patients
suffer with internal tandem duplication mutations of FLT3
(FLT3-ITD+), a membrane associated tyrosine kinase, which
is associated with poor overall survival [31, 35]. A smaller
proportion exhibit mutations of C/EBPa, and the majority
demonstrate alterations in the nucleophosmin (NPM1) gene.
In comparison to FLT3-ITD+ patients, the presence ofNPM1
mutations alone offers a better prognosis [35].
Much like AML, acute lymphocytic leukaemia (ALL) is a
heterogeneous clonal neoplastic disease of the bone marrow,
lymph nodes, thymus, and spleen [46]. It can be subdivided
into T-cell or B-cell ALL, both of which are further defined by
morphology, immunophenotype, and clinical features as well
as cytogenetic aberrations [46]. Over 7,000 cytogenetically
abnormal childhood and adult cases of ALL have been
identified, most of which involve the B-cell lineage [47].
The prevalence of these chromosomal aberrations differs
vastly between adult and child ALL, as is the case with
AML [46]. For example, t(4; 11) which disrupts the mixed
lineage leukaemia (MLL) gene is fourfold more common
in children than adults and t(15; 17), the most common
chromosomal alteration in AML, is never seen in infants
under 12 months with AML [48]. ALL is the most common
type of childhood cancer, but despite widespread efforts into
treatment approaches, up to one-third of patients relapse and
many causes of the malignancy are still undetermined [49].
Evidence suggests that different chromosomal and genetic
subtypes of AML and ALL are associated with differential
miRNA expression. Analysing the role of miRNA in different
leukaemic subtypes may further our understanding of the
oncogenic process in the AML and ALL [49].
A number of deregulated miRNAs in AML have been
shown to be involved in haematopoiesis (miR-130a, miR-
10a, miR-181, miR-451, and miR-155), suggesting that their
aberration might be involved in the oncogenic process [50].
Low levels of let-7b and -c have been identified in different
subtypes of AML [51], and the causal relationship of its dereg-
ulated expression in cancer can be supported by evidence
suggesting it targets a number of genes involved in the cancer
process such as KRAS, TRIM71, nRAS, MYC, and HMGA2
[31].
miR-10a, miR-10b, and members of the miR-29 family
were shown to be overexpressed in mutated NPM1 AML
patients [52]. The genes ofmiR-10a and -b are located within
the HOX clusters and upregulation of these two miRNAs
has been seen in cytogenetically normal AML (CN-AML)
patients in association with HOX gene upregulation [53],
suggesting that miRNA may be regulated by expression of
neighbouring genes. In a study of 30 AML patients, HOXA1,
HOXA13,HOXB1, andHOXB13were the onlyHOX genes not
to show strongly positive or negative correlationwithmiR-10a
and miR-10b [54]. In contrast, these miRNAs have shown to
directly target HOXA1 in the K562 cell line [55]. This might
be explained by the small sample size of the patient study or
the fact that the correlation between miRNA andHOX genes
is specific to species and tissue type [53]. Although the role
of HOX genes in cancer biology has not been fully defined
[53], evidence suggests HOX genes may prevent apoptosis
[55] and HOXA9 has been associated with poor prognosis in
AML [56].
Illustrating that differential miRNA expression might be
dependent on AML subtypes, miR-29 has conversely shown
downregulation inMLL-rearranged AML patients [31]. It has
been suggested thatmiR-29may play a role in tumourigenesis
by inhibiting apoptotic genes such as MCL1, and luciferase
vector assays have validated the direct binding ofmiR-29b to
the 3󸀠UTRofMCL1 [57]. In line with this theory, cells from an
AML patient cohort underwent apoptosis upon reexpression
of miR-29b. Upregulation of miR-24 in AML patients with
t(8; 21) is thought to be caused by binding of the AML-ETO
fusion product to the miRNA gene locus, and overexpression
leads to the downregulation of mitogen-activated protein
kinase phosphatase 7 (MPK7) [58]. Subsequent lack of
inhibition of both c-Jun is thought to cause uncontrolled cell
growth in myeloid leukaemia cells [58].
Also implicated inAML is themiR-15a/16-1 cluster, shown
to act as tumour suppressor genes [59]. This effect might
be mediated through the targeted silencing of BCL2, pro-
grammed cell death protein 4 (PDCD4), and Wilms tumour
1 (WT1) [59, 60], the latter of which is frequently detected
at high levels in AML [60]. An inverse correlation between
this miRNA cluster and WT1 levels was shown in primary
AML blasts in comparison to their normal counterparts [59].
However, luciferase reporter assays identified that this asso-
ciation is notmediated directly throughmiRNA translational
silencing of theWT1mRNA[59] and further research into the
mechanisms ofWT1 silencing in AML patients is warranted.
The miR-17-92 has been reported to act as an oncogene
in lymphoid tissue [61], and miR-17-19b is associated with
the downregulation of p21, an inhibitor of cell cycle progres-
sion [62]. In one study, murine myeloid progenitors were
cotransduced with theMLL-rearrangement (MLL-AF10) and
miR-17-19b, and then transplanted into lethally irradiated
mice. The leukaemia that subsequently developed was more
aggressive than that in mice without miR-17-19b expression
[62]. Along with 19 other genes, p21 is a predicted target of
miR-17-92 and p21 3󸀠UTR shows perfect complementarity to
the seed region ofmiR-17-5p [62]. Knockdown of p21 inMLL-
transduced murine myeloid progenitors mimicked the effect
of miR-17-19b overexpression in MLL-rearranged leukaemia
cells [62]. In T-ALL without MLL-rearrangements, miR-17-
92 has also shown oncogenic potential as induced expression
of miR-19 accelerated the development of ALL in mice [63].
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Figure 3: The dual oncogenic and tumour suppressor nature of
miR-17-92. The transcription factor c-myb induces expression of
both miR-17-92 and E2F1. MiR-17-92 can subsequently act both
as a tumour suppressor gene through inhibition of E2F1 or as an
oncogene via the targeted silencing of tumour suppressor genes such
as PTEN and Bim.
As with many targets of miRNA, four confirmed targets of
miR-19 (Bim, PTEN, PRKAA1, and PP2A) act to negatively
regulate the phosphatidylinositol-3-kinase (PI3K) pathway
[31], suggesting that the oncogenic effect of overexpressed
miR-17-92 in acute leukaemias may be related to the silencing
of these genes.
2.3. Lymphomas. In B-cell lymphomas the c13orf25 gene
located in chromosome 13q31-32 is frequently amplified [64].
Located within this region is miR-17-92, and its subsequent
overexpression has been shown to play an oncogenic role
in these malignancies. Overexpression ofmiR-17-92 in B-cell
lymphomaMYC TGmice accelerated formation of lymphoid
malignancies and mice death [65]. Previously discussed
targets of this cluster include the tumour suppressor PTEN,
the proapoptotic Bim, and the cell cycle regulator E2F1.
Immunoblot analysis and luciferase reporter assays have
confirmedPTEN andBim as direct targets of clustermembers
miR-17-5p/-19 and miR-92, respectively [66], supporting an
oncogenic role for this cluster. In contrast, targeting E2F1
gene suggests a tumour suppressor role. This gene, like miR-
17-92, can be directly upregulated by c-myc. Interestingly,
expression of miR-17-92 in HeLa cells demonstrated a 50%
decrease in E2F1 protein levels, and E2F1 has experimentally
been validated as a direct target of the cluster membersmiR-
17-5p and -20a [67]. This illustrates a mechanism in which
miR-17-92 can tightly regulate c-myc oncogenesis and also
acts as a tumour suppressor gene (Figure 3). Therefore, like
many other miRNAs, miR-17-92 possesses both oncogenic
and tumour suppressor functions depending on the specific
biological context [64]. Interestingly, E2F1 can act to increase
proliferation in some settings and induce apoptosis in others
[68, 69]. If in B-cell lymphomas it acts to induce apoptosis,
its downregulation by miR-17-92 might further define this
cluster as an oncogene.
The overexpression of miR-155 in lymphomas followed
identification of the B-cell integration cluster (BIC) gene
as a common retroviral integration site in avian leucosis
virus (ALV) induced B-cell lymphomas [64], where BIC
represented a conserved stretch of nucleotides corresponding
to pri-miR-155 [70]. Since a 10–60 fold-increase in miR-
155 expression has been identified in aggressive DLBCL [71]
and expression of this miRNA in NK-cell lymphomas has
been associated with decreased levels of SHIP, PTEN, and
PDCD4, all of which are tumour suppressors, suggesting
that inhibition of miR-155 in this T-cell lymphoma drives
tumourigenesis [72]. It is unsurprising that miR-155 plays a
role in B-cell malignancy considering overexpression of this
miRNA in TGmice led to a preleukaemic B-cell proliferation
[73]. This might suggestmiR-155 plays a role early in oncoge-
nesis before secondary events lead to occult malignancy. The
regulation of PU.1 bymiR-155maybe of important pathogenic
significance as this transcription factor regulates late-onset
differentiation of B cells [74].
Interestingly, much like differences in miRNA expression
have been identified between adult and childhood acute
leukaemias, one study identified a 100-fold upregulation of
miR-155 in paediatric Burkitt’s Lymphoma but not in adult
cases [75]. miR-155 deregulation has also shown upregula-
tion in all other haematological malignancies described in
this review suggesting that this miRNA may have multiple
oncogenic functions in different cell types or that all malig-
nanciesmight share a common target fundamental to tumour
suppression [75].
2.4. Multiple Myeloma. Multiple myeloma develops sec-
ondary to a benign monoclonal gammopathy of undeter-
mined significance (MGUS) [76]. Full-blown malignancy
is characterised by excessive proliferation of plasma cells
that infiltrate the bone marrow and produce abnormal
immunoglobulin (M protein) [77].
The survival and expansion of malignant plasma cells are
dependent on signal transducer and activator of transcription
3 (STAT3), secondary to IL-6 signalling [77]. It has been
found that upregulation of the gene encoding the oncogenic
miR-21 is also STAT3 dependent and overexpression can
promote survival of myeloma cells in the absence of IL-6
[78].The contribution ofmiR-21 to STAT3 oncogenic activity
in myeloma is supported by frequent upregulation of this
miRNA in bothMGUS and myeloma patients in comparison
to healthy donors [76, 77]. SOCS proteins mediate inhibition
of the STAT pathways, and downregulation of SOCS1 is
frequent in multiple myeloma [76]. High expression of both
miR-19a andmiR-19b, members of themiR-17-92 cluster, also
targets SOCS1 in myeloma cells [76].
Pichiorri et al. showed upregulation of the miR-106-25
cluster in MGUS patients [76]. Although the sample size was
limited in this study (𝑛 = 6), the findings illustrate deregula-
tion of oncogenic miRNA early in disease progression [76].
The oncogenic potential of miR-106-25 and miR-21 may be
due to targeted downregulation of tumour suppressors such
as PTEN, Bim, and p21 [77]. Through targeting of the latter
two, miR-106-25 has also shown to suppress transforming
growth factor beta (TGFb), which is responsible for cell cycle
arrest and apoptosis [79]. Interestingly, miR-106-25, along
with miR-32 and miR-181a/b, may target the p53 regulator
p300-CBP-associated factor (PCAF), which would reduce
tumour suppressor p53 levels in multiple myeloma [77].
miR-15a/16-1 are also deregulated in over 50% ofmyeloma
patients [77], and patient studies showed significant down-
regulation of miR-15a/16-1 in CD135+ myeloma cells in
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Table 2: Predicted role in oncogenesis of miRNAs analysed within
this review.
Tumour suppressor Oncogenic Dual role in differenthaematological subtypes
miR-15a/16-1 miR-155 miR-17-92
miR-29b miR-96 miR-29c
miR-34a let-7 miR-181a/b
miR-151 miR-24 miR-150
miR-204 miR-21 miR-125
miR-32 miR-10a
miR-106-25 miR-196
Table 3: Evidence to strengthen association of miRNA with
tumourigenesis [75].
1 Widespread deregulation in multiple cancers
2 Gain or loss of miRNA function secondary todeletions, mutation, or amplifications
3 Documentation of tumour suppressor orpromoter activity in animal models
4
Verification of cancer-relevant targets in order to
identify likely mechanisms through which
miRNAs promote oncogenesis
comparison to normal counterparts [80, 81]. Interestingly,
deletion of chromosome 13q14.3 which encodes these two
miRNAs is not significantly associatedwithmyeloma patients
over normal controls [77], and therefore the genetic basis of
their deregulation in myeloma is yet to be fully determined.
At the molecular level, miR-15a/16-1 have been shown to
inhibit cyclin-D1, cyclin-D2, and CDC25A, key regulators
of cell cycle progression [77], as well as protein kinase
B (AKT) and nuclear factor-kappa B (NF-𝜅B) pathways
involved in oncogenesis [80].Most cases ofmultiplemyeloma
demonstrate deregulation of one or more cyclin-D genes
[82], which in this case might be explained by reduced miR-
15a/16-1 levels. Combined with the role of these miRNAs in
lymphomas and leukaemia, miR-15a/16-1 provide evidence
that a single miRNA can have multiple and complex effects
in cell biology [77].
3. Interpretation and Analysis
This review highlights that certain miRNAs may act as
bona fide tumour suppressor genes or oncogenes, alongside
evidence that supports certain miRNAs to have the potential
to act depending on both cell type and context (Table 2).
It has been suggested that four types of evidence can
strengthen the argument for miRNA acting directly as
tumour suppressors or promoters (Table 3) [75]; not only
was the identification of miR-15a/16-1 the first reported
link between miRNA and cancer [12], but also continuous
research has allowed these miRNAs to fulfil all four of these
criteria. They have been found deregulated in a diverse
range of cancers, including CLL, myeloma, lymphomas, and
prostate cancer [1, 83, 84], absent or reduced expression has
been found secondary to deletion of the DLEU2 gene at
chromosome 13q14.3 [19] and/or mutational change [2, 20,
21], evidence for their natural tumour suppressor function
has been supported through various xenograftmousemodels
and in the CLL-prone NZB mouse model [3, 20, 21], and
the antiapoptotic protein Bcl2 [15], as well as others [60, 77],
has been experimentally validated as a direct target of miR-
15a/16-1 [4]. Although many miRNAs analysed in this review
may fulfil one or two of these criteria, miR-17-92 and miR-
155 are othermiRNAs involved in haematologicalmalignancy
able to fulfil all four of these criteria.
Understanding how miRNAs contribute to the six hall-
marks of cancer may also provide solid evidence for their role
in tumourigenesis. This review makes it clear that miRNAs
greatly contribute to enhanced proliferation, differentia-
tion, and reduced apoptosis in haematological malignancies.
Angiogenesis has been highlighted as an important feature
of haematological malignancies, providing a specialised envi-
ronment for HSC proliferation and differentiation through
provision of GM-CSF, G-CSF, and IL-6 shown to be impor-
tant in the proliferation and survival of malignant cells [85].
The oncogenicmiR-17-92 cluster and the tumour suppressors
miR-15a/16-1 have been shown to be proangiogenic and
antiangiogenic, respectively [86, 87]. If miRNAs are able
to promote bone marrow vascularisation in this way, the
secretion of GM-CSF, G-CSF, and IL-6 from these areas of
high vascular density might support a role of miRNA in self-
sufficiency in growth signals, another hallmark of cancer.
Metastasis of haematological cancers to other organs is a rare
phenomenon [88]; these data highlight a role for miRNA in
most hallmarks and increase support for a fundamental role
in oncogenesis.
Additional support for the role of miRNAs in cancer
comes from their association with epigenetic changes. DNA
CpG island hypermethylation of tumour suppressor genes
is a well-characterised aberration in malignant cells, along
with global genomic hypomethylation and histone modi-
fication disturbances [89]. Over half of miRNA genes are
associated with CpG islands [90]. If these miRNAs are
bona fide tumour suppressor genes, their hypermethylation
and subsequent transcriptional silencing will affect cancer
progression [91]. Downregulation ofmiR-34 due to promoter
hypermethylation has been identified in primary samples of
CLL,myeloma, andNHL [92].TheMIR-34a gene is located at
chromosome 1p35, which is subject to loss of heterozygosity
in various cancers [92]. Loss of heterozygosity together with
promoter hypermethylation of this gene fulfils Knudson’s
two-hit hypothesis [19] for bona fide tumour suppressor
genes.
Paradoxically, miRNAmay also directly target epigenetic
machinery [31]. Evidence suggests that miR-29b may target
the DNA methylation agents DNMT1 and DNMT3 [93].
Reexpression ofmiR-29b inAML cells resulted in globalDNA
hypomethylation and subsequent upregulation of tumour
suppressor genes [93]. Further evidence for the association
between miRNA and cancer epigenetics is vast and beyond
the scope of this review.
Importantly, miRNAs are increasingly recognised as
prognostic biomarkers and therapeutic targets in various
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types of haematological malignancies. Briefly focusing on
AML, a few recent studies have attempted to support this
notion. It was found that mir-155 upregulated in patients
with CN-AML was associated with lower remission rates
and higher overall survival rates [94]. The high expression
of miR-155 was interestingly associated with genes widely
known to be deregulated in AML supporting the role of
this miRNA in AML pathogenesis [94]. Recent work on the
role of let-7a showed enhanced chemosensitivity of AML cell
lines overexpressed with let-7a [95]. A miRNA microarray
study using 15 chemoresistant and 18 chemosensitive patients
with AML identified three consistently upregulated miRNAs
associated with therapeutic response. One of these, miR-
363, was further characterised to target the genes RGS17
and HIPK3, which have previously been associated with
therapeutic response in AML patients [96]. These studies
identify that certain miRNA signatures are associated with
the clinical outcome.
There are caveats and difficulties faced within the field
of miRNA research. The benefits of investigating primary
cells and patient cohorts are often reduced due to small
sample size, reducing external validity. As mentioned in
AML and ALL, differences in cytogenetics and therefore
miRNA expression may be age dependent within the same
malignancy. Often studies broadly look at disease without
separating findings to a particular cytogenetic subtype or age
group. A study looking at differences of miRNA expression
between adult and childhood acute leukaemias [31] shows
that this is an important consideration to take into account
when analysing the function of specific miRNAs. Many
studies base much of their interpretation on array- and PCR-
based miRNA profiling studies, which have the disadvantage
of having to already predict which miRNAs are going to
be deregulated. This makes finding novel miRNA associated
with haematological malignancy difficult [97]. Often authors
search for miRNAs that have shown deregulation in solid
tumours, a method that can miss miRNAs important to
haematological cancers. This is of particular relevance con-
sidering many miRNAs have shown to be tissue-specific and
dependent on cellular context, as previously discussed in this
review [97]. It is also important to note that not all studies
reach agreement about miRNA expression in various haema-
tological malignancies. Differences in methodology might
explain this, as many studies likely use different microarray
platforms. A study into the sources of data variability across
microarray platforms identified poor reproducibility between
platforms and across laboratories [98]. Different results in
miRNA expression might also be secondary to differences
in patient samples, as well as the fact that not all studies
used the same cell lines when examining miRNA in vitro.
Additionally, in some studies cell lines were used that were
not indicative of the primary disease. The colonic cancer
RKO cell line was used to investigate miR-10a in CML by
Aggire et al. [36], andmany functional studies ofmiR-15a/16-1
and BCL2 used nonlymphoid cell lines [16]. Different groups
may have used cells at different maturation stages, which
may have an effect on miRNA expression since miR-155 and
miR-106-25 have shown effect early in disease progression
of lymphomas and myeloma, respectively [73, 76]. These
problems call for the need of standardised methodology for
miRNA investigation and an evaluation of the appropriate
experimental approaches to study miRNA in haematological
cancers.
4. Concluding Remarks
It is apparent that there is accumulating evidence for the
role ofmiRNA in haematologicalmalignancies, with different
patterns of expression correlating with distinct types and
subtypes. In this review, evidence from miR-181 and miR-
17-92 illustrates how miRNA can function both as tumour
suppressors and promoters dependent on biological and
cellular context. The well-characterised functions of miR-
15a/16-1 demonstrate that a single miRNA can have far reach-
ing and multiple effects in cells and in cancer progression,
targeting a variety of cancer associated genes. Furthermore,
expression analysis has revealed that certainmiRNAs, such as
miR-155, are deregulated in all haematological malignancies,
suggesting that certain miRNAs may be fundamental to
tumourigenesis.
Our understanding of these small noncoding RNA is con-
tinually evolving andmore recent research highlights areas of
miRNA regulation and function not previously considered or
identified.miRNAswere initially discovered as posttranscrip-
tional silencers of protein-coding genes, and this still remains
true. However, their function andmechanisms by which they
mediate their effects extend further than this. As well as
acting through the RISC complex, they have been shown to
mediate protein inhibition through epigenetic modifications
of proteins involved in tumourigenesis or tumour inhibition
[97]. Evidence also suggests miRNAmay function as a decoy
for other noncoding proteins, as discussed for miR-328 in
CML-BC [39]. Additionally, other groups have identified seed
sequence mutations in miRNA, which may act to alter target
specificity [99]. Finally, Jing et al. demonstrated an extended
role of miR-15a/16-1 showing that in addition to posttran-
scriptional silencing, miR-16 may function to target AU-rich
elements (AREs) in target mRNA, mediating their decay
[100]. Of huge interest is the identification of other highly
conserved noncoding RNA, such as ultraconserved regions
(UCRs) [101], which have shown functional importance in
cell biology [102] and have shown cancer-specific signatures,
including within haematological malignancies [103]. This
provides an additional layer of insight into the nature of
tumourigenesis, especially considering that miRNAs and
UCRshave been shown to interact [104], whichmay influence
complex pathways associated with cancer formation and
progression. Current data and our overall understanding
of miRNA regulation and function have likely only been
touched upon. What is clear is that miRNAs reflect an addi-
tional layer of insight into the haematological malignancies,
and future investigations into their role are warranted given
their promise for therapeutic opportunities.
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